Longbio Pharma

Suzhou, China · Founded 2020 · In IPO Registration

Manufacturer of antibody-based biologics intended for autoimmune and allergic diseases. Longbio Pharma is based in Suzhou, China and was founded in 2020. Its last reported valuation was $278 million in May 2025. It has raised $76.7 million.

Last reported valuation
$277.8M
Oct 2026
Priced at
—
Total raised
$76.7M
Last round
—

Who backs Longbio Pharma?

13 investors
InvestorType
Qiming Venture PartnersVenture capital
Oriental Fortune CapitalVenture capital
Highlight CapitalOther
Shanghai Lingang Economic DevelopmentOther
Ancheng CapitalOther
Shanxi Securities Innovation InvestmentOther
Changshu Guofa Venture Capital—
Hangzhou Betta Investment—
Sanyi Capital (China)—
Shenzhen Sangel Venture Capital—
+ 3 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Longbio Pharma investors

Free account
More of Longbio Pharma with a free account
  • ·The complete investor list: 13 names
  • ·Watch Longbio Pharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 13 firms already write checks for companies like Longbio Pharma. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View